CHI-541 (Spectrum Therapeutics)

CHI-541 is a cannabinoid-based pharmaceutical candidate developed by Spectrum Therapeutics, the medical division of Canopy Growth Corporation. It is a standardized formulation containing specific ratios of delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD), intended for the treatment of chronic pain, nausea, muscle spasticity, and epilepsy. The drug primarily functions by modulating the endocannabinoid system, specifically acting as an agonist at the Cannabinoid receptor 1 (CB1) and Cannabinoid receptor 2 (CB2). CHI-541 has been evaluated in Phase 1 clinical trials (e.g., NCT04114838) to assess its safety, tolerability, and pharmacokinetic profile following multiple-dose administration in healthy volunteers.